Julie VanOrsdel Daves - 01 Jun 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: SVP Clinical Development Oper.
Signature: /s/ Amy E. Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 01 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Jun 2023, 17:16:33 UTC
Previous filing: 15 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						0	01 Jun 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+54,000		$0.000000	54,000	01 Jun 2023	Common Shares	54,000	$2.73	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024.